US FDA Approves Jardiance (empagliflozin) to Treat Adults with Heart Failure Regardless of Left Ventricular Ejection Fraction

RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 24, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news